Search clinical trials for: OXP005

Total 42 results

Peplin
TKL Research, Inc.

Completed

A Multi-center Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on Non-head Locations (Trunk and Extremities)

Actinic Keratosis

United States, Australia
Peplin

Completed

A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

Actinic Keratosis

United States, Australia
Peplin

Completed

Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel

Keratosis

United States
Peplin

Completed

Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses

Actinic Keratosis

Australia
Peplin

Completed

Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma

Basal Cell Carcinoma

Australia
Peplin

Completed

To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC

Superficial Basal Cell Carcinoma

United States
Peplin

Completed

Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses

Actinic Keratosis

United States
Peplin

Withdrawn

The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)

Warts

Australia
Peplin

Completed

Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005

Actinic Keratoses

Australia
Peplin

Completed

Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma In Situ

Carcinoma, Squamous Cell

Australia
Peplin

Completed

Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell Carcinoma

Basal Cell Carcinoma

Australia
Peplin
LEO Pharma

Completed

PEP005 Gel - Evaluation of Local Tolerability After Exposure to Ingenol Mebutate Gel Followed by Hand Washing in Healthy Subjects

Healthy | Actinic Keratosis

United States
Peplin
Omnicare Clinical Research

Completed

A Study to Examine the Safety and Toleration of PEP005 Topical Gel in Patients With Actinic Keratoses on the Top of the Hand

Actinic Keratosis

United States
Peplin

Completed

Safety and Toleration of PEP005 Topical Gel When Applied to a Treatment Area of up to 100cm2

Actinic Keratosis

United States, Australia
Peplin

Completed

A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers

Actinic Keratosis

United States
Peplin

Completed

Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.015%, in Patients With Photo-damaged Skin

Photo-damage

Australia
Peplin

Completed

A Study to Evaluate the Photoirritation Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers

Actinic Keratosis

United States
Peplin

Completed

Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis

Seborrheic Keratosis

Australia
Icahn School of Medicine at Mount Sinai
LEO Pharma

Completed

Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses

Actinic Keratoses

United States
Peplin

Completed

A Multicenter Study to Evaluate the Safety and Efficacy of PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

Actinic Keratosis

United States, Australia
LEO Pharma

Completed

PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology

Actinic Keratosis

Germany
LEO Pharma

Completed

PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy

Actinic Keratosis

Germany
Peplin

Completed

Study to Determine the Sensitizing Potential of PEP005 Topical Gel in Healthy Volunteers Using a Repeat Insult Patch Test Design

Healthy

United States
Xgene Pharmaceutical Pty Ltd

Completed

Phase 1 Pharmacokinetics, Safety, and Tolerability Study

Pain

Australia
Peplin

Completed

A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

Actinic Keratoses

United States, Australia
BiomX, Inc.
Maruho Co., Ltd.

Not yet recruiting

A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis
Peplin

Completed

A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

Actinic Keratoses

United States
Peplin

Completed

A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

Actinic Keratosis

United States, Australia
Xgene Pharmaceutical Pty Ltd

Completed

Phase 1 XG005-03 Topical Study

Pain

Australia
Peplin

Completed

A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis

Actinic Keratosis

United States
Xgene Pharmaceutical Group

Recruiting

XG005 for Pain Control in Subjects Undergoing Bunionectomy

Acute Pain

United States
Tetra Bio-Pharma
McGill University; Santé Cannabis

Terminated

Cannabis Oil and Radiation Therapy for the Management of Pain

Breast Cancer | Lung Cancer | Metastatic Prostate Cancer

Canada
Peplin

Completed

A Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel

Actinic Keratoses

Australia, New Zealand
Peplin

Completed

PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities

Superficial Basal Cell Carcinoma

Australia
Pacira Pharmaceuticals, Inc

Completed

Study of FX005 for the Treatment of Pain in Patients With Osteoarthritis of the Knee

Osteoarthritis, Knee

United Kingdom, Spain, Canada, Austria
Dushu Lake Hospital Affiliated to Soochow University

Recruiting

Natural Killer (NK) Cells (XS005) Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM)

Glioblastoma | GBM

China
Xspray Pharma AB

Completed

Evaluating the Pharmacokinetic Parameters and Relative Bioavailability of Sorafenib (XS005) in Healthy Male Subjects

Pharmacokinetics | Bioavailability

United Kingdom
Oxford Pharmascience Ltd

Completed

Pilot Study of OXP005 to Assess Gastroduodenal Irritation

Gastroduodenal Erosions

United Kingdom
Oxford Pharmascience Ltd

Completed

Phase I Study PK Study With OXP005 and Naprosyn

Pharmacokinetics

United Kingdom
Oxford Pharmascience Ltd

Completed

Pilot Study of OXP001 and Brufen in Healthy Subjects

NSAID Related Gastric Irritation

United Kingdom
Mitovie Pharma Ltd

Unknown

Naloxone Nasal Spray Pharmacokinetic Study

Opioid Overdose

Jordan
Xgene Pharmaceutical Pty Ltd

Completed

Pharmacokinetics Study of XG005 Capsule

Pain

Australia

3

Subscribe